Sign in
Active, not recruitingPhase 3

Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

Key facts

Who runs it
Hellenic Institute for the Study of Sepsis
Where
Greece29 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
330 people, planned
Started
15 Feb 2024
Expected to end
28 Feb 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Clarithromycin 500mg
  • Tablets
Record updated
18 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (29)Hide the full registry criteria

Who can take part

  • Age equal to or above 18 years
  • Male or female gender
  • In case of women of reproductive age, willingness to use dual contraceptive method during the study period
  • Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation
  • Community-acquired pneumonia (CAP)
  • Presence of at least two of the following signs: i) cough; ii) purulent sputum expectoration; iii) dyspnea; and/or iv) pleuritic chest pain
  • PCT ≥0.25 ng/ml
  • suPAR ≥6 ng/ml

Who cannot take part

  • Oral or IV intake of corticosteroids at a daily dose equal to or greater than 0.4 mg/kg prednisone for a period greater than the last 15 days
  • Concomitant oral intake of astemizole, cizapride, doperidone, pimozide, terfenadine, midazolam, ranolazine, ergot alkaloids (e.g. ergotamine and dihydroergotamine), lomitapide and colchicine; patients may be enrolled in the trial if they stop these drugs during trial participation
  • Concomitant intake of lovostatin or simvastatin; patients may be enrolled in the trial if they stop these drugs during trial participation
  • Concomitant presence of end-stage liver failure and end-stage renal failure
  • Any stage IV malignancy
  • Infection by SARS-CoV-2
  • Known infection by the human immunodeficiency virus
  • Medical history of allergy to macrolides
  • Medical history of torsades de pointes arrhythmia
  • QTc interval at rest in the ECG ≥500 msec or history of know long QT syndrome
  • Age below 18 years
  • Denial of written informed consent
  • Any do not resuscitate decision
  • Patients necessitating non-invasive ventilation or mechanical ventilation
  • Hospitalization in Intensive Care Unit
  • Intake of any macrolide for the current episode of CAP under study
  • Any chronic anti-cytokine treatment for more than two months
  • Severe hypokalemia or severe hypomagnesemia; a patient may be enrolled one any of these electrolyte disturbances are restored
  • Any contradictions for macrolide uptake
  • Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study
  • Participation in any other interventional trial within the last 30 days

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early start of adjunctive oral clarithromycin guided by suPAR to prevent the progression into sepsis in patients with community-acquired pneumonia (CAP) at risk. This can be achieved by endpoints incorporating clinical benefit with the effect of treatment on the improvement of the immune dysregulation of CAP. The secondary objectives of REACT are to investigate the impact of early adjunctive treatment with clarithromycin on the resolution of CAP at the test-of-cure (TOC) visit.

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    These patients will be treated with 1 placebo tablet every 12 hours and it is suggested that all patients receive at least one of antibiotics based on the current ESCMID guidelines for severe CAP13 (Ampicillin/sulbactam, Amoxicillin/clavulanate, Piperacillin/tazobactam, Ceftriaxone, Cefotaxime, Ceftaroline, Moxifloxacin). The total duration of treatment will be seven days.Τhe dosage, the dosage regime, the route and mode of administration, and the treatment period for the aforementioned antibiotics can be found in the relevant SmPCs (available in References). However, the attending physician may modify the antimicrobial treatment based on risk factors for multidrug-resistance pathogens, microbiology results and local epidemiology. All SoC treatment products and clarithromycin are authorised for use in Greece, where the trial will be conducted.

    Treatment: Tablets

  • ClarithromycinExisting treatment, for comparison

    These patients will be treated with oral clarithromycin 500 mg twice daily for seven days and it is suggested that all patients receive at least one of antibiotics based on the current ESCMID guidelines for severe CAP13 (Ampicillin/sulbactam, Amoxicillin/clavulanate, Piperacillin/tazobactam, Ceftriaxone, Cefotaxime, Ceftaroline, Moxifloxacin). The total duration of treatment will be seven days.Τhe dosage, the dosage regime, the route and mode of administration, and the treatment period for the aforementioned antibiotics can be found in the relevant SmPCs (available in References). However, the attending physician may modify the antimicrobial treatment based on risk factors for multidrug-resistance pathogens, microbiology results and local epidemiology. All SoC treatment products and clarithromycin are authorised for use in Greece, where the trial will be conducted.

    Treatment: Clarithromycin 500mg

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Biomarker-Guided Early Elarithromycin Treatment to Prevent Sepsis Progression in Community-Acquired Pneumonia: The React Randomized Clinical Trial
Record updated
18 November 2026